AbbVie Seeks Approval for Lung Cancer Candidate Teliso-V [Yahoo! Finance]
ANI Pharmaceuticals, Inc. (ANIP)
Last ani pharmaceuticals, inc. earnings: 2/27 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
anipharmaceuticals.com/investors_corporate_profile.php
Company Research
Source: Yahoo! Finance
AbbVie ABBV announced that it has submitted a biologics license application (BLA) to the FDA seeking accelerated approval for its investigational antibody-drug conjugate (ADC) telisotuzumab vedotin (Teliso-V) for previously treated EGFR wild type non-squamous non-small cell lung (NSCLC) cancer in adult patients with c-Met overexpression. Currently, there are no FDA-approved therapies for treating c-Met overexpressing NSCLC. If approved, Teliso-V will become the first-in-class therapy for the given indication. Year to date, shares of AbbVie have rallied 25.7% compared with the industry‘s 20.2% rise. Image Source: Zacks Investment Research BLA Based on ABBV's LUMINOSITY Study The above BLA, which seeks an accelerated nod for Teliso-V in c-Met overexpressing NSCLC, was based on data from the phase II LUMINOSITY study. The company announced encouraging top-line data from the phase II LUMINOSITY study last November. Data from the study showed that study participants treate
Show less
Read more
Impact Snapshot
Event Time:
ANIP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIP alerts
High impacting ANI Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ANIP
News
- Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? [Yahoo! Finance]Yahoo! Finance
- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $94.00 price target on the stock.MarketBeat
- ANI Pharmaceuticals Inc (ANIP) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics [Yahoo! Finance]Yahoo! Finance
- ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance [Yahoo! Finance]Yahoo! Finance
ANIP
Earnings
- 11/8/24 - Beat
ANIP
Sec Filings
- 11/20/24 - Form 8-K
- 11/18/24 - Form 4
- 11/18/24 - Form 4
- ANIP's page on the SEC website